Protalix BioTherapeutics Reports Positive Long Term Data on PRX-102 for Fabry Disease
October 19, 2015 at 07:33 AM EDT
Protalix BioTherapeutics, Inc. (NYSE MKT: PLX) (TASE:PLX), announced today positive long term data from the 0.2mg, or lowest dose, of ...